Kytopen Awarded NIH Grant of Up to $2M to Unlock the Power of Engineered Natural Killer (NK) Cells via Flowfect® Platform

Health and medicine

Home » Health and medicine

The 221b Foundation Grants License to ALBOT Technologies to Develop, Manufacture and Distribute CRISPR COVID-19 Diagnostic Kits in India

Sherlock™ CRISPR SARS-CoV-2 Kit to be Distributed Across Government Labs and Facilities to Meet Diagnostic Testing Needs Across the Region June 15, 2021 08:30 AM Eastern Daylight Time BOSTON–(BUSINESS...

AbSci Announces Acquisition of Target Discovery Company Totient

Nautilus Biotechnology Debuts as Publicly Traded Company, Seeks to Deliver on the Untapped Potential of the Human Proteome

Business combination transaction with Arya Sciences Acquisition Corp III, a special purpose acquisition company sponsored by Perceptive Advisors, closed on June 9, 2021 Publicly traded company renamed Nautilus...

Codexis and Takeda Expand Strategic Collaboration and License Agreement to Discover Additional Gene Therapy for a Fourth Rare Genetic Disorder

10x Genomics Unlocks Whole Transcriptome Analysis in FFPE Tissues With New Visium Assay, Now Shipping

Cronos Group and Ginkgo Bioworks Amend Agreement to Accelerate Commercialization of Cultured Cannabinoids and Cronos Group Begins Commercial Production of CBG

Centivax and U.S. Naval Medical Research Center Announce Strategic Partnership to Initiate Clinical Development of a Broad-Spectrum Injectable For COVID-19, With $4.2M From the Henry Jackson Foundation

Sherlock Biosciences Announces Initial Results of Automation Study with NorDx Laboratories on CRISPR-based Test for SARS-CoV-2

Hyasynth announces production of >20 rare cannabinoids by fermentation & US patent grant on novel biosynthesis pathway

Herophilus Appoints Sharath Hegde, Ph.D. as Chief Scientific Officer as it Scales Drug Discovery Effort for Complex Brain Diseases

Senti Bio and BlueRock Therapeutics Enter Collaboration to Develop Gene Circuit-Engineered Cell Therapies for Regenerative Medicine

Engine Biosciences Announces $43 Million Series A Round to Decipher Genetic Codes for New Medicines Through Machine Learning and Next-Generation Combinatorial Genetics